Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V L Stauffer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Annals of Pharmacotherapy|April 9, 1998
Potential macrolide interaction with verapamilJ A Steenbergen, V L Stauffer
The Journal of Clinical Psychiatry|December 6, 2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapineB J Kinon, B R Basson, J A Gilmore, et al.
European Journal of Neurology|November 7, 2019
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trialsD D Ruff, J H Ford, A Tockhorn-Heidenreich, et al.
European Journal of Neurology|February 14, 2020
Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'P J Goadsby, G M Terwindt, D D Ruff, et al.
Psychological Medicine|October 8, 2010
The heterogeneity of antipsychotic response in the treatment of schizophreniaM Case, V L Stauffer, H Ascher-Svanum, et al.
Pharmacopsychiatry|January 8, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-beingD Naber, S Kollack-Walker, J Chen, et al.
The Pharmacogenomics Journal|May 20, 2009
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophreniaB A Fijal, B J Kinon, S Kapur, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Annals of Pharmacotherapy|April 9, 1998
Potential macrolide interaction with verapamilJ A Steenbergen, V L Stauffer
The Journal of Clinical Psychiatry|December 6, 2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapineB J Kinon, B R Basson, J A Gilmore, et al.
European Journal of Neurology|November 7, 2019
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trialsD D Ruff, J H Ford, A Tockhorn-Heidenreich, et al.
European Journal of Neurology|February 14, 2020
Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'P J Goadsby, G M Terwindt, D D Ruff, et al.
Psychological Medicine|October 8, 2010
The heterogeneity of antipsychotic response in the treatment of schizophreniaM Case, V L Stauffer, H Ascher-Svanum, et al.
Pharmacopsychiatry|January 8, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-beingD Naber, S Kollack-Walker, J Chen, et al.
The Pharmacogenomics Journal|May 20, 2009
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophreniaB A Fijal, B J Kinon, S Kapur, et al.
Pageof 1